Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperpolarized 13-C-Pyruvate Magnetic Resonance Spectroscopic Imaging Reproducibilty Pilot in Patients With Prostate Cancer

NCT03581500 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03581500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03581500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperpolarized 13-C-Pyruvate Magnetic Resonance Spectroscopic Imaging Reproducibilty Pilot in Patients With Prostate Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
February 6, 2019
Completion date
October 16, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, psa level greater than ten, stage iib prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8